Archon Partners’s Neurogene NGNE Stock Holding History

Archon Partners’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-945	Closed	-$268K	–	62
2017 Q3	$268K	Buy	945 +45	+5%	+$12.9K	0.06%	57
2017 Q2	$253K	Buy	900 +275	+44%	+$78.7K	0.06%	57
2017 Q1	$209K	Buy	+625	New	+$220K	0.05%	59

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Archon Partners's NGNE Position: Q4 2017 in Review

Archon Partners sold out of Neurogene (NGNE) in Q4 2017, closing a stake of 945 shares — an estimated $268K sold.

Archon Partners first reported a position in NGNE in Q1 2017 and held it in 3 quarters. The position peaked at $268K in Q3 2017. 52 funds tracked by Wall St. Rank hold NGNE as of Q4 2017.

Archon Partners reported no remaining Neurogene position as of Q4 2017 after selling out during the quarter.
Archon Partners sold 945 Neurogene shares in Q4 2017, an estimated $268K.
Archon Partners first reported a position in Neurogene in Q1 2017 and held it in 3 quarters.
Archon Partners's Neurogene position peaked at $268K in Q3 2017.
52 funds tracked by Wall St. Rank held Neurogene as of Q4 2017.

Based on Archon Partners's 13F filing for Q4 2017, filed 5 Feb 2018.